Your session is about to expire
← Back to Search
Triple Therapy for Ovarian Cancer
Study Summary
This trial is studying olaparib, durvalumab, and tremelimumab to treat patients with ovarian, fallopian tube, or primary peritoneal cancer.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2023 Phase 3 trial • 154 Patients • NCT02184195Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My ovarian cancer did not improve with initial treatment.My cancer responded to platinum-based treatment and I've been off this treatment for over 6 months.My ovarian, fallopian tube, or peritoneal cancer responds to platinum treatment or is resistant, and I have a genetic test report.My ovarian cancer has come back after initially responding to treatment.My ovarian cancer is still present after initial treatment.My cancer returned or got worse within 6 months after platinum chemotherapy.I have a harmful BRCA1 or BRCA2 gene mutation.My cancer has a BRCA1 or BRCA2 mutation.I have a genetic mutation affecting DNA repair.My cancer shows a high level of genetic changes linked to HR deficiency.
- Group 1: Treatment (olaparib, tremelimumab, durvalumab)
- Approved for 10 Other Conditions - This treatment demonstrated efficacy for 10 other conditions.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is this study still looking for participants?
"The clinical trial hosted on clinicaltrials.gov is no longer recruiting patients for participation. Although this study has completed, there are still 3928 other trials that are ongoing and actively enrolling individuals."
What have researchers found in terms of the potential risks of Olaparib?
"While there is some evidence of its safety, olaparib only received a 2 because there is no data currently supporting efficacy."
To your knowledge, are there any other similar studies currently being conducted?
"Olaparib has undergone 502 clinical trials since the first one in 2005. The initial study, which was completed in Phase 1 and sponsored by AstraZeneca, only involved 98 patients. However, over the past 16 years 744 trials have been completed for Olaparib across 1845 cities and 65 countries."
What are the goals of this clinical trial?
"According to the trial sponsor's reporting, the primary outcome-- which will be observed over a 6 month period-- is the incidence of dose-limiting toxicities (DLTs). This study will also assess secondary outcomes like overall survival and anti-tumor immune response."
How many individuals are included in this clinical research project?
"This trial has concluded its recruitment process. The study was first announced on 6/29/2017 and received its last update on 9/8/2022. However, there are presently 3426 trials actively admitting participants with relapse and 502 studies for Olaparib that are still looking for patients."
How is Olaparib utilized in medical treatment?
"Olaparib has potential as a disease-modifying treatment for conditions like pharmacotherapy, primary peritoneal cancer, and advance directives."
Are there any other existing trials that use Olaparib as a treatment?
"At the moment, there are 502 clinical trials underway that are researching Olaparib. Out of those, 74 are in Phase 3. Although a majority of the trials for Olaparib are based in Houston, Texas, there are 20095 locations around the world running studies for this treatment."
Share this study with friends
Copy Link
Messenger